How Do They Work?

Both drugs target two hormone pathways, but they do it differently.

MariTide

MariTide is a two-in-one molecule:

1. It blocks the GIP receptor. The idea is that this nudges your body toward burning more fat.
2. It activates the GLP-1 receptor, which reduces appetite and slows digestion.

Blocking one pathway while activating the other is the novel piece. Nothing else on the market does this.

Mounjaro (tirzepatide)

Mounjaro takes a different angle:

1. It activates both GIP and GLP-1 receptors.
2. That combination helps control blood sugar, lowers appetite, and may bump up energy use.

The Key Difference

MariTide blocks GIP. Mounjaro activates it. Both activate GLP-1. Which approach is better for weight loss is still an open question. The trials haven't been head-to-head yet.

How Well Do They Work?

MariTide: Early Results

Phase I trial highlights:

• Highest dose: 14.5% body weight loss in 85 days.
• Lowest dose: 7.4% weight loss after just three doses.
• Weight loss held up to 150 days after the last dose.

These are small, short trials. Bigger studies are needed before anyone can really claim how MariTide stacks up long-term.

Mounjaro: Proven Track Record

Mounjaro has been through larger trials and is FDA-approved for type 2 diabetes:

• In the main weight loss trial, average weight loss was 15% to 21% over 72 weeks.
• The 15mg dose got the best results.
• Results outperformed Ozempic in head-to-head comparisons.

Comparing the Two

A few caveats before you draw conclusions:

• MariTide data is early and from small Phase I trials. Mounjaro has completed Phase III.
• The trial timeframes are very different. 85 days vs 72 weeks.
• MariTide's sustained effect after stopping is the unique finding. Mounjaro doesn't show this.

Mounjaro is the more proven drug. MariTide's potential is interesting, but it still has to clear larger trials.

Dosing and Side Effects

MariTide

• Subcutaneous injection.
• Possibly monthly dosing, or less often.
• Trials suggest the dose can be tapered down over time.

Side effects in early trials:

• Mild nausea and vomiting, typical for GLP-1 drugs.
• Generally well tolerated.
• Long-term effects still unknown.

Mounjaro

• Subcutaneous injection, once a week.
• Starts at a low dose and titrates up.

Side effects:

• Nausea, diarrhea, vomiting, constipation, abdominal pain.
• Usually mild to moderate and they improve over time.
• Rare serious risks include pancreatitis and thyroid tumours.

The Practical Differences

1. Frequency. Monthly MariTide vs weekly Mounjaro.
2. Long-term safety data. Mounjaro has it. MariTide doesn't yet.
3. Tapering. MariTide may allow it. Mounjaro doesn't.

Convenient dosing matters, but safety and effectiveness matter more. The next round of MariTide trials will tell us if the early advantages hold up.

What Stands Out About Each Drug

MariTide: The Sticky Effect

1. Weight loss persisted up to 150 days after the last dose in early trials.
2. Possibly monthly dosing instead of weekly.
3. The mechanism is novel: GIP blockade plus GLP-1 activation.

If those features hold up in Phase II and III, MariTide could shift obesity treatment from continuous medication to periodic "top-ups."

Mounjaro: The Proven Option

1. Some of the highest average weight loss numbers of any approved obesity drug.
2. Works for both diabetes and weight loss. Useful since the two conditions often overlap.
3. FDA-approved with a well-characterised safety profile.

Mounjaro is already reshaping diabetes care and is on track to become the standard in medical weight loss.

What This Means for Obesity Treatment

• More effective drugs in the toolkit.
• More room to match the drug to the patient.
• A clearer recognition that obesity is a chronic condition that needs ongoing management.
• Maybe less stigma as treatment options become normal medical practice.

The Bigger Picture

Drugs aren't the whole answer. Diet, exercise, and behavioural change still matter. But the medication side of weight management has gotten genuinely better over the last few years, and it's about to get better still.

If you're weighing options, talk to a clinician who knows your full medical picture.

Disclaimer: This blog post is intended for educational purposes only and should not be taken as medical advice. Always consult your healthcare provider for personal health concerns.